Cargando…

Epileptogenicity of white matter lesions in cerebral small vessel disease: a systematic review and meta-analysis

BACKGROUND: The epileptogenic properties of white matter lesions (WML) in cerebral small vessel disease (CSVD) are not yet understood. The aim of our systematic review and meta-analysis was to estimate the association between the extent of WML in CSVD and epilepsy, analyze whether these WML are asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Doerrfuss, Jakob I., Hebel, Jonas M., Holtkamp, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511556/
https://www.ncbi.nlm.nih.gov/pubmed/37341807
http://dx.doi.org/10.1007/s00415-023-11828-6
_version_ 1785108168128331776
author Doerrfuss, Jakob I.
Hebel, Jonas M.
Holtkamp, Martin
author_facet Doerrfuss, Jakob I.
Hebel, Jonas M.
Holtkamp, Martin
author_sort Doerrfuss, Jakob I.
collection PubMed
description BACKGROUND: The epileptogenic properties of white matter lesions (WML) in cerebral small vessel disease (CSVD) are not yet understood. The aim of our systematic review and meta-analysis was to estimate the association between the extent of WML in CSVD and epilepsy, analyze whether these WML are associated with an increased risk of seizure recurrence, and evaluate if treatment with anti-seizure medication (ASM) is justified in first-seizure patients with WML and no cortical lesions. METHODS: Following a pre-registered study protocol (PROSPERO-ID CRD42023390665), we systematically searched Pubmed and Embase for relevant literature comparing WML load between patients with epilepsy and controls as well as studies on seizure recurrence risk and ASM therapy in the presence vs. absence of WML. We calculated pooled estimates using a random effects model. RESULTS: Eleven studies comprising 2983 patients were included in our study. Presence of WML (OR 2.14, 95% CI 1.38–3.33) and presence of relevant WML as assessed by visual rating scales (OR 3.96, 95% CI 2.55–6.16) but not WML volume (OR 1.30, 95% CI 0.91–1.85) were significantly associated with seizures. These results stayed robust in sensitivity analyses restricted to studies on patients with late-onset seizures/epilepsy. Only two studies assessed the association between WML and risk of seizure recurrence with conflicting results. Currently, there are no studies on the efficacy of ASM therapy in the presence of WML in CSVD. CONCLUSIONS: This meta-analysis suggests an association between presence of WML in CSVD and seizures. More research is needed addressing the association between WML and risk of seizure recurrence and ASM therapy focusing on a population of patients with a first unprovoked seizure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11828-6.
format Online
Article
Text
id pubmed-10511556
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-105115562023-09-22 Epileptogenicity of white matter lesions in cerebral small vessel disease: a systematic review and meta-analysis Doerrfuss, Jakob I. Hebel, Jonas M. Holtkamp, Martin J Neurol Original Communication BACKGROUND: The epileptogenic properties of white matter lesions (WML) in cerebral small vessel disease (CSVD) are not yet understood. The aim of our systematic review and meta-analysis was to estimate the association between the extent of WML in CSVD and epilepsy, analyze whether these WML are associated with an increased risk of seizure recurrence, and evaluate if treatment with anti-seizure medication (ASM) is justified in first-seizure patients with WML and no cortical lesions. METHODS: Following a pre-registered study protocol (PROSPERO-ID CRD42023390665), we systematically searched Pubmed and Embase for relevant literature comparing WML load between patients with epilepsy and controls as well as studies on seizure recurrence risk and ASM therapy in the presence vs. absence of WML. We calculated pooled estimates using a random effects model. RESULTS: Eleven studies comprising 2983 patients were included in our study. Presence of WML (OR 2.14, 95% CI 1.38–3.33) and presence of relevant WML as assessed by visual rating scales (OR 3.96, 95% CI 2.55–6.16) but not WML volume (OR 1.30, 95% CI 0.91–1.85) were significantly associated with seizures. These results stayed robust in sensitivity analyses restricted to studies on patients with late-onset seizures/epilepsy. Only two studies assessed the association between WML and risk of seizure recurrence with conflicting results. Currently, there are no studies on the efficacy of ASM therapy in the presence of WML in CSVD. CONCLUSIONS: This meta-analysis suggests an association between presence of WML in CSVD and seizures. More research is needed addressing the association between WML and risk of seizure recurrence and ASM therapy focusing on a population of patients with a first unprovoked seizure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11828-6. Springer Berlin Heidelberg 2023-06-21 2023 /pmc/articles/PMC10511556/ /pubmed/37341807 http://dx.doi.org/10.1007/s00415-023-11828-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Doerrfuss, Jakob I.
Hebel, Jonas M.
Holtkamp, Martin
Epileptogenicity of white matter lesions in cerebral small vessel disease: a systematic review and meta-analysis
title Epileptogenicity of white matter lesions in cerebral small vessel disease: a systematic review and meta-analysis
title_full Epileptogenicity of white matter lesions in cerebral small vessel disease: a systematic review and meta-analysis
title_fullStr Epileptogenicity of white matter lesions in cerebral small vessel disease: a systematic review and meta-analysis
title_full_unstemmed Epileptogenicity of white matter lesions in cerebral small vessel disease: a systematic review and meta-analysis
title_short Epileptogenicity of white matter lesions in cerebral small vessel disease: a systematic review and meta-analysis
title_sort epileptogenicity of white matter lesions in cerebral small vessel disease: a systematic review and meta-analysis
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511556/
https://www.ncbi.nlm.nih.gov/pubmed/37341807
http://dx.doi.org/10.1007/s00415-023-11828-6
work_keys_str_mv AT doerrfussjakobi epileptogenicityofwhitematterlesionsincerebralsmallvesseldiseaseasystematicreviewandmetaanalysis
AT hebeljonasm epileptogenicityofwhitematterlesionsincerebralsmallvesseldiseaseasystematicreviewandmetaanalysis
AT holtkampmartin epileptogenicityofwhitematterlesionsincerebralsmallvesseldiseaseasystematicreviewandmetaanalysis